# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATIONDECISION SUMMARYASSAY AND INSTRUMENT

I Background Information:

# B Applicant

DiaSorin Molecular LLC

# C Proprietary and Established Names

Simplexa VZV Swab Direct, Simplexa VZV Positive Control Pack

# D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>PGI</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.3309 - HerpesVirus Nucleic Acid-BasedCutaneous AndMucocutaneous LesionPanel</td><td rowspan=1 colspan=1>MI - Microbiology</td></tr><tr><td rowspan=1 colspan=1>PMN</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.3920 -Assayed quality controlmaterial for clinicalmicrobiology assays</td><td rowspan=1 colspan=1>MI - Microbiology</td></tr></table>

# II Submission/Device Overview:

A Purpose for Submission:

To obtain a substantial equivalence determination and FDA clearance for a new device.

B Measurand: Varicella-zoster virus DNA

# C Type of Test:

Realtime Polymerase Chain Reaction

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

B Indication(s) for Use: Simplexa™ VZV Swab Direct

The DiaSorin Molecular Simplexa™ VZV Swab Direct assay is intended for use on the LIAISON $\textsuperscript { \textregistered }$ MDX instrument for the qualitative detection of varicella-zoster virus (VZV) DNA present in cutaneous and mucocutaneous lesion swabs from patients with signs and symptoms of VZV infection. This test is intended as an aid in the diagnosis of VZV infection. Negative results do not preclude VZV infection and should not be used as the sole basis for treatment or other patient management decisions.

Simplexa™ VZV Positive Control Pack

The Simplexa™ VZV Positive Control Pack is intended to be used as a control with the Simplexa™ VZV Direct kit and the Simplexa™ VZV Swab Direct kit on the LIAISON $\textsuperscript { \textregistered }$ MDX instrument. It is not intended for use with other assays or systems.

C Special Conditions for Use Statement(s): Rx - For Prescription Use Only

D Special Instrument Requirements:

LIAISON MDX instrument

# IV Device/System Characteristics:

# A Device Description:

The Simplexa VZV Swab Direct assay is a real-time PCR system that enables the direct amplification and detection of VZV DNA from unprocessed cutaneous and mucocutaneous lesion swab specimens without nucleic acid extraction. The system consists of the Simplexa VZV Swab Direct assay, the LIAISON MDX (with LIAISON MDX Studio Software), the Direct Amplification Disc (DAD) and associated accessories.

In the Simplexa VZV Swab Direct assay, fluorescent probes are used together with corresponding forward and reverse primers to amplify VZV and internal control targets. A wellconserved region of the VZV DNA polymerase gene is targeted to identify VZV DNA in the specimen. An internal control is used to detect PCR failure and/or inhibition.

# B Principle of Operation:

Nucleic acid amplification testing (NAAT)

# C Instrument Description Information:

<table><tr><td rowspan=1 colspan=1>Modes of Operation</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>Does the applicant&#x27;s device contain the ability to transmit data to a computer,webserver, or mobile device?</td><td rowspan=1 colspan=1>—</td><td rowspan=1 colspan=1>X</td></tr><tr><td rowspan=1 colspan=1>Does the applicant&#x27;s device transmit data to a computer, webserver, or mobile deviceusing wireless transmission?</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>X</td></tr><tr><td rowspan=1 colspan=3>Software</td></tr><tr><td rowspan=1 colspan=1>FDA has reviewed applicant&#x27;s Hazard Analysis and software development processesfor this line of product types.</td><td rowspan=1 colspan=1>X</td><td rowspan=1 colspan=1></td></tr></table>

1. Instrument Name: LIAISON MDX

2. Specimen Identification: N/A

3. Specimen Sampling and Handling: N/A

4. Calibration: N/A

# V Substantial Equivalence Information:

A Predicate Device Name(s): Solana HSV 1+2/VZV Assay   
B Predicate 510(k) Number(s): K162451

C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">K192376</td><td colspan="1" rowspan="1">K162451</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">Simplexa VZV Swab Direct Solana HSV 1+2/VZV Assay</td><td colspan="1" rowspan="1">Simplexa VZV Swab Direct Solana HSV 1+2/VZV Assay</td></tr><tr><td colspan="3" rowspan="1">General Device Characteristic Similarities</td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indications for Use</td><td colspan="1" rowspan="1">The DiaSorin MolecularSimplexa VZV Swab Direct</td><td colspan="1" rowspan="1">The Solana HSV 1+2/VZVAssay is an in vitro diagnostic</td></tr><tr><td></td><td>assay is intended for use on the LIAISON MDX instrument for the qualitative detection of varicella-zoster virus (VZV) DNA present in cutaneous and mucocutaneous lesion swabs from patients with signs and symptoms of VZV infection. This test is intended as an aid in the diagnosis of VZV infection. Negative results do not preclude VZV infection and should not be used as the sole basis for treatment or other patient management decisions.</td><td>test, using isothermal amplification technology (helicase-dependent amplification, HDA), for the qualitative detection and differentiation of herpes simplex virus type 1, herpes simplex virus type 2, and varicella-zoster virus DNA isolated and purified from cutaneous or mucocutaneous lesion samples obtained from symptomatic patients suspected of active herpes simplex virus 1, herpes simplex virus 2 and/or Varicella-zoster infection. The Solana HSV 1+2/VZV Assay is intended to aid in the diagnosis of herpes simplex virus 1, herpes</td></tr><tr><td></td><td></td><td>Assay is intended for use only with the Solana instrument.</td></tr><tr><td>Automated System</td><td>Yes</td><td>Yes</td></tr><tr><td>Technology</td><td>Nucleic acid amplification</td><td>Same</td></tr><tr><td>General Device Characteristic Differences</td><td></td><td></td></tr><tr><td>Instrument</td><td>LIAISON MDX</td><td>Solana instrument</td></tr></table>

# VI Standards/Guidance Documents Referenced:

N/A

VII Performance Characteristics (if/when applicable):

A Analytical Performance:

# 1. Precision/Reproducibility:

Reproducibility for the Simplexa VZV Swab Direct assay was evaluated at three (3) investigative sites to assess the device's inter-site, inter/intra-day and inter/intra-assay reproducibility. Each of the laboratories tested a sample panel consisting of Simplexa VZV Swab Direct Positive Control, No Template Control, and four (4) contrived samples in negative matrix. Two (2) strains of VZV were used in the study, 9939 and Ellen. The four (4) contrived samples consisted of a low positive (LP) at $2 \mathbf { x }$ LoD and a medium positive (MP) at 4x LoD for each VZV strain. Each sample panel member was tested in triplicate per run, for two (2) runs per day by two (2) different operators at each site. Therefore, a total of ninety (90) replicates [three (3) replicates x two (2) runs x five (5) days x three (3) sites] were tested for each sample panel member. A total of six (6) LIAISON MDX instruments [two (2) per site] were used. The combined results for all sites are presented in Table 1.

Table 1. Simplexa VZV Swab Direct Reproducibility   

<table><tr><td rowspan=1 colspan=9>Summary of VZV Qualitative Results and VZV Ct Values ± SD (%CV)</td></tr><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=1 colspan=2>Site 1</td><td rowspan=1 colspan=2>Site 2</td><td rowspan=1 colspan=2>Site 4</td><td rowspan=1 colspan=2>All Sites</td></tr><tr><td rowspan=1 colspan=1>%AgreementWithExpectedResults</td><td rowspan=1 colspan=1>DetectedMean Ct ±SD (%CV)</td><td rowspan=1 colspan=1>%AgreementWithExpectedResults</td><td rowspan=1 colspan=1>DetectedMean Ct ±SD (%CV)</td><td rowspan=1 colspan=1>%AgreementWithExpectedResults</td><td rowspan=1 colspan=1>DetectedMean Ct ±SD (%CV)</td><td rowspan=1 colspan=1>%AgreementWithExpectedResults</td><td rowspan=1 colspan=1>DetectedMean Ct ±SD (%CV)</td></tr><tr><td rowspan=1 colspan=1>9939 LP</td><td rowspan=1 colspan=1>100.0%(30/30)</td><td rowspan=1 colspan=1>36.6 ± 1.12(3.1%)</td><td rowspan=1 colspan=1>100.0%(30/30)</td><td rowspan=1 colspan=1>36.8 ± 0.68(1.9%)</td><td rowspan=1 colspan=1>100.0%(30/30)</td><td rowspan=1 colspan=1>36.4 ± 0.83(2.3%)</td><td rowspan=1 colspan=1>100.0%(90/90)</td><td rowspan=1 colspan=1>36.6 ± 0.9(2.5%)</td></tr><tr><td rowspan=1 colspan=1>9939 MP</td><td rowspan=1 colspan=1>100.0%(30/30)</td><td rowspan=1 colspan=1>35.8 ± 0.86(2.4%)</td><td rowspan=1 colspan=1>100.0%(30/30)</td><td rowspan=1 colspan=1>35.7 ± 0.54(1.5%)</td><td rowspan=1 colspan=1>100.0%(30/30)</td><td rowspan=1 colspan=1>35.3 ± 0.78(2.2%)</td><td rowspan=1 colspan=1>100.0%(90/90)</td><td rowspan=1 colspan=1>35.6 ± 0.76(2.1%)</td></tr><tr><td rowspan=1 colspan=1>Ellen LP</td><td rowspan=1 colspan=1>100.0%(30/30)</td><td rowspan=1 colspan=1>35.4 ± 1.22(3.4%)</td><td rowspan=1 colspan=1>100.0%(30/30)</td><td rowspan=1 colspan=1>34.5 ± 1.77(5.1%)</td><td rowspan=1 colspan=1>100.0%(30/30)</td><td rowspan=1 colspan=1>35.0 ± 0.56(1.6%)</td><td rowspan=1 colspan=1>100.0%(90/90)</td><td rowspan=1 colspan=1>35.0 ± 1.32(3.8%)</td></tr><tr><td rowspan=1 colspan=1>Ellen MP</td><td rowspan=1 colspan=1>100.0%(30/30)</td><td rowspan=1 colspan=1>34.5 ± 0.65(1.9%)</td><td rowspan=1 colspan=1>100.0%(30/30)</td><td rowspan=1 colspan=1>34.5 ± 0.47(1.4%)</td><td rowspan=1 colspan=1>100.0%(30/30)</td><td rowspan=1 colspan=1>33.5 ± 1.3(3.9%)</td><td rowspan=1 colspan=1>100.0%(90/90)</td><td rowspan=1 colspan=1>34.1 ± 0.99(2.9%)</td></tr><tr><td rowspan=1 colspan=1>UTM(NTC)</td><td rowspan=1 colspan=1>0.0%(0/30)</td><td rowspan=1 colspan=1>0.0 ± 0.00(N/A)</td><td rowspan=1 colspan=1>0.0%(0/30)</td><td rowspan=1 colspan=1>0.0 ± 0.00(N/A)</td><td rowspan=1 colspan=1>0.0%(0/30)</td><td rowspan=1 colspan=1>0.0 ± 0.00(N/A)</td><td rowspan=1 colspan=1>0.0%(0/90)</td><td rowspan=1 colspan=1>0.0 ± 0.00(N/A)</td></tr><tr><td rowspan=1 colspan=1>PC</td><td rowspan=1 colspan=1>100.0%(30/30)</td><td rowspan=1 colspan=1>30.2 ± 0.74(2.5%)</td><td rowspan=1 colspan=1>100.0%(30/30)</td><td rowspan=1 colspan=1>30.4 ± 0.59(1.9%)</td><td rowspan=1 colspan=1>100.0%(30/30)</td><td rowspan=1 colspan=1>29.7 ± 0.86(2.9%)</td><td rowspan=1 colspan=1>100.0%(90/90)</td><td rowspan=1 colspan=1>30.1 ± 0.79(2.6%)</td></tr></table>

2. Linearity: N/A

# 3. Analytical Specificity/Interference:

Cross-Reactivity (Analytical Specificity): The Simplexa VZV Swab Direct assay’s analytical specificity was evaluated by testing the ability of the assay to exclusively identify VZV with no cross-reactivity to organisms that are closely related, cause similar clinical symptoms or that could be found in cutaneous and mucocutaneous lesion swab specimens. Analytical specificity/cross-reactivity was tested with ninety-nine (99) different bacteria, viruses, parasites and fungi and assayed in triplicate. No cross-reactivity was observed with the ninety-nine (99) organisms. The organisms and the concentration at which these were tested are presented in Table 2.

Table 2. Simplexa VZV Swab Direct Cross-Reactivity   

<table><tr><td colspan="1" rowspan="1">Organism</td><td colspan="1" rowspan="1">Tested Concentration</td><td colspan="1" rowspan="1">Organism</td><td colspan="1" rowspan="1">Tested Concentration</td></tr><tr><td colspan="1" rowspan="1">Acholeplasma laidlawi(genomic DNA)</td><td colspan="1" rowspan="1">1 x 106 copies/mL</td><td colspan="1" rowspan="1">Human genomic DNA</td><td colspan="1" rowspan="1">1 x 106 copies/mL</td></tr><tr><td colspan="1" rowspan="1">Acinetobactercalcoaceticus</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Human metapneumovirusA1</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Acinetobacter lwoffi</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Human Papilloma Virus18</td><td colspan="1" rowspan="1">1 x 105 copies/mL</td></tr><tr><td colspan="1" rowspan="1">Adenovirus 7A</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">InfluenzaA/California/7/2009</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Bacteroides fragilis</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">InfluenzaB/Florida/02/2006</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Bordetella bronchiseptica</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Bordetella pertussis</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Lactobacillus acidophilus</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Borrelia burgdorferi(genomic DNA)</td><td colspan="1" rowspan="1">1 x 106 copies/mL</td><td colspan="1" rowspan="1">Legionella pneumophila</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Candida albicans</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Measles virus</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Candida glabrata</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Mobiluncus curtisii</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Candida guilliermondii</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Mobiluncus mulieris</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Candida krusei</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Moraxella cartarrhalis</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Candida lusitaniae</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Mumps virus</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Candida parapsilosis</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Mycoplasma genitalium</td><td colspan="1" rowspan="1">1 x 106 CCU/mL</td></tr><tr><td colspan="1" rowspan="1">Candida tropicalis</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Mycoplasma hominis</td><td colspan="1" rowspan="1">1 x 106 CCU/mL</td></tr><tr><td colspan="1" rowspan="1">Chlamydia trachomatis</td><td colspan="1" rowspan="1">1 x 106 IFU/mL</td><td colspan="1" rowspan="1">Mycoplasma hyorhinis</td><td colspan="1" rowspan="1">1 x 106 CCU/mL</td></tr><tr><td colspan="1" rowspan="1">Chlamydophilapneumoniae</td><td colspan="1" rowspan="1">1 x 106 IFU/mL</td><td colspan="1" rowspan="1">Mycoplasma orale</td><td colspan="1" rowspan="1">1 x 106 CCU/mL</td></tr><tr><td colspan="1" rowspan="1">Clostridium difficile</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Mycoplasma pneumoniae</td><td colspan="1" rowspan="1">1 x 106 CCU/mL</td></tr><tr><td colspan="1" rowspan="1">Clostridium perfringens</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Mycoplasma salivarium</td><td colspan="1" rowspan="1">1 x 106 CCU/mL</td></tr><tr><td colspan="1" rowspan="1">Clostridium sordellii</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Neisseria gonorrhoeae</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Coronavirus OC43</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Neisseria meningitidis</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Corynebacteriumdiphtheriae</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Parainfluenza Type 1</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Corynebacteriumgenitalium</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Parainfluenza Type 2</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Coxsackievirus B1</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Parainfluenza Type 3</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Coxsackievirus B4</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Parainfluenza Type 4</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Cytomegalovirus (AD169strain)</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Prevotellamelaninogenica</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Cytomegalovirus (Townestrain)</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Proteus mirabilis</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Echovirus 11</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Proteus vulgaris</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Enterobacter cloacae</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Pseudomonas aeruginosa</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Enterococcus faecalisvanB</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">RSV A Long</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Enterococcus faecium</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">RSV B Washington</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Enterovirus 70</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Rubella Virus</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Enterovirus 71</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Salmonella enteritidis(genomic DNA)</td><td colspan="1" rowspan="1">1 x 106 copies/mL</td></tr><tr><td colspan="1" rowspan="1">Epstein Barr Virus (B95-8 strain)</td><td colspan="1" rowspan="1">1 x 105 copies/mL</td><td colspan="1" rowspan="1">Salmonella typhimurium</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Escherichia coli O15:H7</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Serratia marcescens</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Fusobacterium nucleatum</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Simian Virus type 40</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Gardnerella vaginalis</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Staphylococcus aureus(MRSA), ATCC 700699</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Haemophilus ducreyi</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Staphylococcus aureus(MRSA), COL</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Haemophilus influenzatype A</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Staphylococcusepidermidis (MRSE),ATCC 29887</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Hepatitis A virus</td><td colspan="1" rowspan="1">1 x 106 TCID50/mL</td><td colspan="1" rowspan="1">Staphylococcussaprophyticus</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Hepatitis B virus</td><td colspan="1" rowspan="1">1 x 105 IU/mL</td><td colspan="1" rowspan="1">Streptococcus agalactiae</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Hepatitis C virus</td><td colspan="1" rowspan="1">1 x 105 IU/mL</td><td colspan="1" rowspan="1">Streptococcus mitis</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">HHV-6 (Z29 strain)</td><td colspan="1" rowspan="1">1 x 105 copies/mL</td><td colspan="1" rowspan="1">Streptococcus mutans</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">HHV-6A</td><td colspan="1" rowspan="1">1 x 105 copies/mL</td><td colspan="1" rowspan="1">Streptococcuspneumoniae</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">HHV-7 SB</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Streptococcus pyogenes,M1</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">HHV-8</td><td colspan="1" rowspan="1">1 x 105 copies/mL</td><td colspan="1" rowspan="1">Streptococcus salivarius</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">HIV-1 IIIB</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Toxoplasma gondii</td><td colspan="1" rowspan="1">1 x 106 tachyzoites/mL</td></tr><tr><td colspan="1" rowspan="1">HIV-2 NIHZ</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Trichomonas vaginalis</td><td colspan="1" rowspan="1">1 x 106 trophozoites/mL</td></tr><tr><td colspan="1" rowspan="1">HSV-1 (McIntyre strain)</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Ureaplasma urealyticum</td><td colspan="1" rowspan="1">1 x 106 CCU/mL</td></tr><tr><td colspan="1" rowspan="1">HSV-2 (G strain)</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr></table>

Note: Bacteroides ureolyticus, Hepatitis D virus, Treponema pallidum and Tropheryma whipplei were tested using in silico NCBI BLAST analysis due to unavailability of the organism. No cross-reactivity was found.

Inhibition by other Microorganisms: The Simplexa VZV Swab Direct assay was evaluated by testing the ability to identify VZV virus (Ellen and 9939 strains) when other potentially inhibitory organisms are present. A panel of ninety-nine (99) potential inhibitory organisms was individually spiked into pooled cutaneous and mucocutaneous swab matrix containing a low concentration of VZV at approximately 2X LoD and tested in triplicate. Table below references the microorganisms and their respective tested concentration. No inhibition was observed for the detection of either VZV Ellen or 9939 strain.

Table 3. Simplexa VZV Swab Direct Microbial Inhibition   

<table><tr><td colspan="1" rowspan="1">Organism</td><td colspan="1" rowspan="1">Tested Concentration</td><td colspan="1" rowspan="1">Organism</td><td colspan="1" rowspan="1">Tested Concentration</td></tr><tr><td colspan="1" rowspan="1">Acholeplasma laidlawi(genomic DNA)</td><td colspan="1" rowspan="1">1 x 106 copies/mL</td><td colspan="1" rowspan="1">Human genomic DNA</td><td colspan="1" rowspan="1">1 x 106 copies/mL</td></tr><tr><td colspan="1" rowspan="1">Acinetobactercalcoaceticus</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Human metapneumovirusA1</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Acinetobacter lwoffi</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Human papilloma virus 18</td><td colspan="1" rowspan="1">1 x 105 copies/mL</td></tr><tr><td colspan="1" rowspan="1">Adenovirus 7A</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">InfluenzaA/California/7/2009</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Bacteroides fragilis</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">InfluenzaB/Florida/02/2006</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Bordetella bronchiseptica</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Bordetella pertussis</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Lactobacillus acidophilus</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Borrelia burgdorferi(genomic DNA)</td><td colspan="1" rowspan="1">1 x 106 copies/mL</td><td colspan="1" rowspan="1">Legionella pneumophila</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Candida albicans</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Measles virus</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Candida glabrata</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Mobiluncus curtisii</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Candida guilliermondii</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Mobiluncus mulieris</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Candida krusei</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Moraxella cartarrhalis</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Candida lusitaniae</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Mumps virus</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Candida parapsilosis</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Mycoplasma genitalium</td><td colspan="1" rowspan="1">1 x 106 CCU/mL</td></tr><tr><td colspan="1" rowspan="1">Candida tropicalis</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Mycoplasma hominis</td><td colspan="1" rowspan="1">1 x 106 CCU/mL</td></tr><tr><td colspan="1" rowspan="1">Chlamydia trachomatis</td><td colspan="1" rowspan="1">1 x 106 IFU/mL</td><td colspan="1" rowspan="1">Mycoplasma hyorhinis</td><td colspan="1" rowspan="1">1 x 106 CCU/mL</td></tr><tr><td colspan="1" rowspan="1">Chlamydophilapneumoniae</td><td colspan="1" rowspan="1">1 x 106 IFU/mL</td><td colspan="1" rowspan="1">Mycoplasma orale</td><td colspan="1" rowspan="1">1 x 106 CCU/mL</td></tr><tr><td colspan="1" rowspan="1">Clostridium difficile</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Mycoplasma pneumoniae</td><td colspan="1" rowspan="1">1 x 106 CCU/mL</td></tr><tr><td colspan="1" rowspan="1">Clostridium perfringens</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Mycoplasma salivarium</td><td colspan="1" rowspan="1">1 x 106 CCU/mL</td></tr><tr><td colspan="1" rowspan="1">Clostridium sordellii</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Neisseria gonorrhoeae</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Coronavirus OC43</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Neisseria meningitidis</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Corynebacteriumdiphtheriae</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Parainfluenza Type 1</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Corynebacteriumgenitalium</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Parainfluenza Type 2</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Coxsackievirus B1</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Parainfluenza Type 3</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Coxsackievirus B4</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Parainfluenza Type 4</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Cytomegalovirus (AD169strain)</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Prevotella melaninogenica</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Cytomegalovirus (Townestrain)</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Proteus mirabilis</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Echovirus 11</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Proteus vulgaris</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Enterobacter cloacae</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Pseudomonas aeruginosa</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Enterococcus faecalisvanB</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">RSV A Long</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Enterococcus faecium</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">RSV B Washington</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Enterovirus 70</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Rubella Virus</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Enterovirus 71</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Salmonella enteritidis(genomic DNA)</td><td colspan="1" rowspan="1">1 x 106 copies/mL</td></tr><tr><td colspan="1" rowspan="1">Epstein Barr Virus (B95-8strain)</td><td colspan="1" rowspan="1">1 x 105 copies/mL</td><td colspan="1" rowspan="1">Salmonella typhimurium</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Escherichia coli O15:H7</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Serratia marcescens</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Fusobacterium nucleatum</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Simian Virus type 40</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td></tr><tr><td colspan="1" rowspan="1">Gardnerella vaginalis</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Staphylococcus aureus(MRSA), ATCC 700699</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Haemophilus ducreyi</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Staphylococcus aureus(MRSA), COL</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Haemophilus influenzatype A</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td><td colspan="1" rowspan="1">Staphylococcusepidermidis (MRSE),ATCC 29887</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Hepatitis A virus</td><td colspan="1" rowspan="1">1 x 106 TCID50/mL</td><td colspan="1" rowspan="1">Staphylococcussaprophyticus</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Hepatitis B virus</td><td colspan="1" rowspan="1">1 x 105 IU/mL</td><td colspan="1" rowspan="1">Streptococcus agalactiae</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">Hepatitis C virus</td><td colspan="1" rowspan="1">1 x 105 1U/mL</td><td colspan="1" rowspan="1">Streptococcus mitis</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">HHV-6 (Z29 strain)</td><td colspan="1" rowspan="1">1 x 105 copies/mL</td><td colspan="1" rowspan="1">Streptococcus mutans</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">HHV-6A</td><td colspan="1" rowspan="1">1 x 105 copies/mL</td><td colspan="1" rowspan="1">Streptococcus pneumoniae</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">HHV-7 SB</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Streptococcus pyogenes,M1</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">HHV-8</td><td colspan="1" rowspan="1">1 x 105 copies/mL</td><td colspan="1" rowspan="1">Streptococcus salivarius</td><td colspan="1" rowspan="1">1 x 106 CFU/mL</td></tr><tr><td colspan="1" rowspan="1">HIV-1 IIIB</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Toxoplasma gondii</td><td colspan="1" rowspan="1">1 x 106 tachyzoites/mL</td></tr><tr><td colspan="1" rowspan="1">HIV-2 NIHZ</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Trichomonas vaginalis</td><td colspan="1" rowspan="1">1 x 106 trophozoites/mL</td></tr><tr><td colspan="1" rowspan="1">HSV-1 (McIntyre strain)</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1">Ureaplasma urealyticum</td><td colspan="1" rowspan="1">1 x 106 CCU/mL</td></tr><tr><td colspan="1" rowspan="1">HSV-2 (G strain)</td><td colspan="1" rowspan="1">1 x 105 TCID50/mL</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr></table>

Note: Bacteroides ureolyticus, Hepatitis D virus, Treponema pallidum and Tropheryma whipplei were tested using in silico NCBI BLAST analysis due to unavailability of the organism. No interference was found.

Interference: The performance of the Simplexa VZV Swab Direct assay was evaluated with potentially interfering substances. The tested concentrations of the potential interfering endogenous and exogenous substances ar e indicated in the table below. A total of forty-five (45) potential interfering substances were individually spiked into a pooled cutaneous and mucocutaneous swab matrix containing a low concentration of VZV at approximately 2X LoD and tested in triplicate. No interference was observed as shown below.

Table 4. Simplexa VZV Swab Direct Interference   

<table><tr><td colspan="1" rowspan="1">Potentially InterferingSubstance.</td><td colspan="1" rowspan="1">VZV Strain</td><td colspan="1" rowspan="1">Active Ingredient</td><td colspan="1" rowspan="1">TestedConcentration</td><td colspan="1" rowspan="1"># Detected/# Tested</td></tr><tr><td colspan="1" rowspan="2">Abreva</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">Docosanol 10%</td><td colspan="1" rowspan="2">7% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Acetaminophen</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">7% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Acyclovir</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">10 mg/mL</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Albumin</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">10 mg/mL</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Balneol lotion</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">Buffers, emulsifiers, PEG,water, mineral oil, lanolin oil,preservatives</td><td colspan="1" rowspan="2">7% (v/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Carmex</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">Camphor, 1.7%; Menthol, 0.7%</td><td colspan="1" rowspan="2">10% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Casein</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">10 mg/mL</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Chlor-Trimeton</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">Chlorpheniramine maleate</td><td colspan="1" rowspan="2">5 mg/mL</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Cidofovir</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">2.5 mg/mL</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Clotrimazole VaginalCream</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">Clotrimazole</td><td colspan="1" rowspan="1">7% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3.5% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Cold-Eeze</td><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="2">Zincum Gluconicum 2X</td><td colspan="1" rowspan="1">5% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="1">2.5% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Cornstarch</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">1.25 mg/mL</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Denavir</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">2.5 mg/mL</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="3">Desitin</td><td colspan="1" rowspan="2">9939</td><td colspan="1" rowspan="3">Zinc Oxide, 40%</td><td colspan="1" rowspan="1">7% (w/v)</td><td colspan="1" rowspan="1">2/2</td></tr><tr><td colspan="1" rowspan="1">3.5% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3.5% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Dextromethorphanhydrobromide(Robitussin-DM)</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">Dextromethorphanhydrobromide</td><td colspan="1" rowspan="2">10 mg/mL</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Douche</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">7% (v/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Famciclovir</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">2.5 mg/mL</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Feces</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">2.5 mg/mL</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Foscarnet</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">1.25 mg/mL</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Glucose</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">11 mg/mL</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Gynol II contraceptivejelly</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">Nonoxynol-9 (3%)</td><td colspan="1" rowspan="2">7% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Human genomic DNA</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">20 μg/mL</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Immunoglobulin</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">10 mg/mL</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">KY Jelly</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="1">10 mg/mL</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">5%(w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Lactate</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">2.2 mg/mL</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Lanacane</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="1">Benzethonium chloride, 0.2%;</td><td colspan="1" rowspan="2">7% (v/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">Benzocaine, 20%</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Lip-Clear Lysine</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">Zinc Oxide, 1.2%</td><td colspan="1" rowspan="1">7% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3.5% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Miconazole 1</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">Miconazole nitrate, 26%</td><td colspan="1" rowspan="2">10% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Miconazole 3</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">Miconazole nitrate, 2%</td><td colspan="1" rowspan="2">10% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Monistat 1 insert</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">Miconazole nitrate, 1200 mg</td><td colspan="1" rowspan="2">7% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Monistat 3 cream</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">Miconazole nitrate 2%</td><td colspan="1" rowspan="2">7% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Mouthwash (Listerine)</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="1">Eucalyptol, 0.092%; Menthol,</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">0.042%; Methyl salicylate,0.060%; Thymol, 0.064%</td><td colspan="1" rowspan="1">7% (v/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Mucin</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">5% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Preparation H</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">10% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Releev</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">10% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Seminal Fluid</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">10% (v/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Tioconazole 1</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">10% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Toothpaste (Colgate)</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">Sodium fluoride, 0.243%</td><td colspan="1" rowspan="2">7% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Urine</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">10% (v/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Vagisil creme</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">Benzocaine (5%), Resorcinol(2%)</td><td colspan="1" rowspan="2">7% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Valacyclovir</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">2.5 mg/mL</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Valgancyclovir</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">2.5 mg/mL</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">White blood cells</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">5.5x107 cells/mL</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">Whole Blood in EDTA</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">N/A</td><td colspan="1" rowspan="2">10% (v/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="2">YeastGard suppositories</td><td colspan="1" rowspan="1">9939</td><td colspan="1" rowspan="2">Candida albicans 27X HPU(Candida albicans), Candidaparapsilosis 27X HPUS(Candida parapsilosis),Pulsatilla 27X HPUS (MeadowAnemone)</td><td colspan="1" rowspan="2">7% (w/v)</td><td colspan="1" rowspan="1">3/3</td></tr><tr><td colspan="1" rowspan="1">Ellen</td><td colspan="1" rowspan="1">3/3</td></tr></table>

6. Detection Limit:

The limit of detection (LoD) was determined for the Simplex VZV Swab Direct assay using quantified stocks of two (2) VZV strains (Ellen and 9939) in a pool of cutaneous and mucocutaneous lesion swab sample types UTM matrix. The LoD was determined to be the lowest concentration that could be detected positive $2 9 5 \%$ of the time. The LoD for each strain is presented in Table 5.

Table 5. Simplexa VZV Swab Direct Assay Limit of Detection   

<table><tr><td rowspan=1 colspan=1>VZV Strain</td><td rowspan=1 colspan=1>LoD (TCID50/mL)</td><td rowspan=1 colspan=1>LoD (Copies /mL)</td></tr><tr><td rowspan=1 colspan=1>993</td><td rowspan=1 colspan=1>0.77</td><td rowspan=1 colspan=1>800</td></tr><tr><td rowspan=1 colspan=1>Elle</td><td rowspan=1 colspan=1>0.054</td><td rowspan=1 colspan=1>3500</td></tr></table>

7. Assay Cut-Off: N/A

8. Accuracy (Instrument): N/A

# 9. Carry-Over:

The amplification carry-over for the Simplexa assays including the Simplexa VZV Swab Direct was assessed from the Simplexa Flu A/B & RSV Direct viral assay study. The study can be applied to the Simplexa VZV Swab Direct assay as the study is not analyte specific. In the Simplexa Flu A/B & RSV Direct, the amplification carry-over study was performed to determine the potential for contamination when negative samples are tested adjacent to strong positive samples. The study was designed by alternately placing high positive and negative samples on each disc. No evidence of carry-over contamination was observed.

# B Comparison Studies:

1. Method Comparison with Predicate Device:

# Clinical Studies

The performance of the Simplexa VZV Swab Direct assay was established in a clinical study that included three cohorts based on sample status. Specifically, prospective and retrospective cutaneous and mucocutaneous swab samples from human patients with signs and symptoms of VZV infection, as well as contrived samples, were tested in the clinical agreement study.

Prospective Study: A total of four hundred fifty-two (452) cutaneous and mucocutaneous prospective specimens were collected from ten collection sites across the USA during the clinical study (November 2018 – May 2019). The specimens were taken from anorectal, genital, nasal, ocular, oral, skin and urethral locations of the body. The age of the patients ranged from one month to greater than 60 years of age. Of these specimens, $6 2 . 4 \%$ of the specimens were from female patients and $3 7 . 6 \%$ of the specimens were from male patients. Ten testing sites performed the Simplexa VZV Swab Direct assay on enrolled specimens and shipped the specimens to two comparator testing sites to test against a three part composite reference method (CRM). The three part CRM consisted of VZV direct stain fluorescent antibody (DSFA) and/or culture isolation with direct fluorescent antibody (DFA) and two validated VZV polymerase chain reaction (PCR) assays followed by bi-directional sequencing. The comparator testing was performed by two sites. One testing site performed the VZV DSFA and/or culture isolation with DFA and another testing site conducted the two validated VZV PCR assays testing followed by bi-directional sequencing. The results of the study are presented in Table 6.

Table 6. Simplexa VZV Swab Direct Prospective Agreement Results   

<table><tr><td rowspan=4 colspan=1>ProspectiveStudy</td><td rowspan=1 colspan=4>Composite ReferenceMethod (CRM)</td><td rowspan=4 colspan=1>Total</td><td rowspan=4 colspan=1>Sensitivity95% CI</td><td rowspan=4 colspan=1>Specificity95% CI</td></tr><tr><td rowspan=1 colspan=2>+</td><td rowspan=1 colspan=2>-</td></tr><tr><td rowspan=1 colspan=2>SimplexaVZV SwabDirect</td><td rowspan=1 colspan=2>SimplexaVZV SwabDirect</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td></tr><tr><td rowspan=1 colspan=1>Mucocutaneous</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>1a</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>171</td><td rowspan=1 colspan=1>179</td><td rowspan=1 colspan=1>87.5% (7/8)52.9% - 97.8%</td><td rowspan=1 colspan=1>100.0% (171/171)97.8% - 100.0%</td></tr><tr><td rowspan=1 colspan=1>Cutaneous</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>1b</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>162</td><td rowspan=1 colspan=1>245</td><td rowspan=1 colspan=1>98.8% (79/80)93.3% - 99.8%</td><td rowspan=1 colspan=1>98.2% (162/165)94.8% - 99.4%</td></tr><tr><td rowspan=1 colspan=1>Unknown</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>100.0% (1/1)20.7% - 100.0%</td><td rowspan=1 colspan=1>100.0% (27/27)87.5% - 100.0%</td></tr><tr><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>452</td><td rowspan=1 colspan=1>97.8% (87/89)92.2% -99.4 %</td><td rowspan=1 colspan=1>99.2% (360/363)97.6% - 99.7%</td></tr></table>

a The discordant negative mucocutaneous result is from an oral lesion sample. The sample was negative by the Simplexa VZV Swab Direct, DSFA/DFA and by the sites routine culture testing. The sample was positive by the two (2) PCR/Bi-directional sequencing assays. b The discordant negative cutaneous result is from a skin lesion sample. The sample was negative by the Simplexa VZV Swab Direct, DSFA/DFA testing. The sample was positive by the 2 PCR/Bidirectional sequencing assays. c $\mathrm { C I } =$ Confidence Interval. The $9 5 \%$ confidence intervals (CI) were calculated following Wilson Score method.

Retrospective Study: A total of sixty (60) cutaneous and mucocutaneous retrospective positive swab specimens in UTM were blinded and randomized with one hundred twenty (120) negative masked specimens prior to being tested by Simplexa VZV Swab Direct assay. The Composite Reference Method 2 (CRM 2) utilized a two out of three outcomes from one FDA Cleared NAAT PCR assay for VZV and two validated VZV PCR assays followed by bi-directional sequencing. The FDA Cleared NAAT was performed by one external site. DiaSorin Molecular performed the Simplexa VZV Swab Direct testing and different DiaSorin Molecular operators performed the two validated VZV PCR assays followed by bi-directional sequencing. The positive and negative percent agreement (PPA and NPA) results of the study are presented in Table 7.

Table 7. Simplexa VZV Swab Direct Retrospective Agreement Results   

<table><tr><td rowspan=4 colspan=1>RetrospectiveStudy</td><td rowspan=1 colspan=4>Composite ReferenceMethod 2(CRM 2)</td><td rowspan=4 colspan=1>Total</td><td rowspan=4 colspan=1>PPA95% CIb</td><td rowspan=4 colspan=1>NPA95% CI</td></tr><tr><td rowspan=1 colspan=2>+</td><td rowspan=1 colspan=2>•</td></tr><tr><td rowspan=1 colspan=2>SimplexaVZV SwabDirect</td><td rowspan=1 colspan=2>SimplexaVZV SwabDirect</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td></tr><tr><td rowspan=1 colspan=1>Mucocutaneous</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1a</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>90.0% (9/10)59.6% - 98.2%</td><td rowspan=1 colspan=1>100.0% (63/63)94.3% - 100.0%</td></tr><tr><td rowspan=1 colspan=1>Cutaneous</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=1>100.0% (52/52)93.1% - 100.0%</td><td rowspan=1 colspan=1>98.2% (54/55)90.4% - 99.7%</td></tr><tr><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>98.4% (61/62)91.4% - 99.7%</td><td rowspan=1 colspan=1>99.2% (117/118)95.4% - 99.9%</td></tr></table>

a The discordant negative mucocutaneous result is from an oral lesion sample. The sample was negative by the Simplexa VZV Swab Direct and NAAT testing. The sample was positive by the two (2) PCR/Bi-directional sequencing assays. ${ } ^ { \mathsf { b } } { \mathrm { C I } } =$ Confidence Interval. The $9 5 \%$ confidence intervals (CI) were calculated following Wilson Score method.

Contrived Sample Study: A total of sixty (60) contrived positive specimens in individual negative UTM mucocutaneous swab matrix were blinded and randomized with sixty (60) masked negative UTM mucocutaneous specimens prior to being tested by Simplexa VZV Swab Direct assay. The results were compared with a two out of three outcomes from one FDA Cleared NAAT assay and two validated VZV PCR assays followed by bi-directional sequencing (Composite Reference Method 2 or CRM 2). Of the sixty (60) contrived specimens, thirty (30) were spiked with VZV Ellen strain and thirty (30) were spiked with VZV 9939 strain at different known concentrations across the detection range. The results are presented in Table 8.

Table 8. Simplexa VZV Swab Direct Contrived Agreement Results   

<table><tr><td rowspan=4 colspan=1>ContrivedMucocutaneousSamples</td><td rowspan=1 colspan=4>Composite ReferenceMethod 2(CRM 2)</td><td rowspan=4 colspan=1>Total</td><td rowspan=4 colspan=1>PPA95% CIa</td><td rowspan=4 colspan=1>NPA95% CI</td></tr><tr><td rowspan=1 colspan=2>+</td><td rowspan=1 colspan=2>-</td></tr><tr><td rowspan=1 colspan=2>SimplexaTMVZV SwabDirect</td><td rowspan=1 colspan=2>SimplexaTMVZV SwabDirect</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td></tr><tr><td rowspan=1 colspan=1>Ellen</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>100.0% (30/30)88.6% - 100.0%</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>9939</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>100.0% (30/30)88.6% - 100.0%</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>60/60 (100%)94.0% -100.0%</td></tr><tr><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>100.0% (60/60)94.0% - 100.0%</td><td rowspan=1 colspan=1>100.0% (60/60)94.0% - 100.0%</td></tr></table>

a $\mathrm { C I } =$ Confidence Interval. The $9 5 \%$ confidence intervals (CI) were calculated following Wilson Score method.

# C Clinical Studies:

1. Clinical Sensitivity: N/A

2. Clinical Specificity: N/A

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): N/A

D Clinical Cut-Off: N/A

# E Expected Values/Reference Range:

In the prospective clinical study 452 cutaneous and mucocutaneous samples were tested by Simplexa VZV Swab Direct. The values for VZV detection per site varied between $0 \%$ and $7 5 \%$ The overall expected value for all sites is $1 9 . 9 \%$ . The expected values per site are presented in Table 9 below.

Table 9. VZV Incidence as Determined by Simplexa VZV Swab Direct   

<table><tr><td rowspan=1 colspan=1>Site ID</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1># Detected</td><td rowspan=1 colspan=1>VZV Incidence% Detected</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>75.0%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>39.9%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>31.3%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>34.2%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>25.0%</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.9%</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>139</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>11.5%</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>53.6%</td></tr><tr><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>452</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>19.9%</td></tr></table>

# F Other Supportive Instrument Performance Characteristics Data: N/A

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.